Abstract 1655P
Background
The overexpression of MAP17, a small non-glycosylated membrane protein, has been described in a wide variety of human carcinomas, correlating with worse prognosis and response to different therapies. Pancreatic cancer (PC) has been the seventh major cause of cancer-related deaths worldwide in 2020, associated to a high mortality with a life expectancy of ∼5% at 5 years. Its aggressiveness makes necessary to identify new targets/biomarkers of response. The aim of this study was to assess the prognostic and predictive value of MAP17 expression in PC.
Methods
We evaluated MAP17 expression by immunohistochemistry in a cohort of 97 paraffin-embedded tissue samples of patients. We overexpressed MAP17 in two PC cells lines and tumorigenesis was analyzed using different functional assays and measuring several stem cell markers. We performed IC50 assays with different drugs and correlated them with MAP17 expression. Finally, we explored the effect of some of those treatments in vivo.
Results
High expression of MAP17 was detected only in pancreatic tumor cells. Also, we found that the overexpression of MAP17 increased the tumorigenic and stemness properties of cells as PC cell lines with high levels of MAP17 grew faster, formed higher number of colonies, holoclones, tumorspheres and a higher proportion of CD133+ cells. We explored whether the response to different antitumoral agents could be dependent on MAP17 expression, detecting that MAP17-expressing PC cells showed better response to gemcitabine, 5-FU, cisplatin and osimertinib, as well as resistance to docetaxel, bortezomib and ixazomib. However, in tumor xenografts in vivo, MAP17 expression confers resistance to all treatments. Next, we detected that the levels of total NAD, an essential metabolite implicated in many cellular processes, were higher in cells that overexpress MAP17. Finally, we found that the use of different inhibitors of NAMPT, the limiting enzyme of the synthesis of NAD, re-sensitize pancreatic tumor xenografts to classic chemotherapy.
Conclusions
MAP17 could serve as a prognostic and predictive biomarker in PC. Moreover, our findings could open new options of coadjuvant to current therapy with cisplatin or gemcitabine in PC that may eventually improve patients' outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AC lab was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00 and RTI2018-096735-B-I00 grant from AEI-MICIU/FEDER (RED2018-102723-T); from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejeria de Salud (PI-0397-2017) and Consejeria of Economía, Conocimiento, Empresas y Universidad of the Junta de Andalucia (P18-RT-2501). Especial thanks to the AECCFoundation for supporting this work. EMV-S was funded by a postdoctoral contract from Consejería de Transformacion Economica, Industria, Conocimiento, y Universidades of the Junta de Andalucia, Spain ( CTEICU/PAIDI 2020 , DOC_01655). JM-P was funded by a Rio Hortega contract from Instituto de Salud Carlos III (ISCIII, CM18/00219).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1644P - The mutation landscape and evolution pattern of liver or peritoneal metastasis in pancreatic cancer
Presenter: Guoliang Yao
Session: Poster session 22
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22